COMPOSITIONS FOR SUPPRESSING CANCER BY INHIBITION OF TMCC3

(19)

(11)

EP 3 123 173 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	16.12.2020 Bulletin 2020/51

(45)	Mention of the grant of the patent:
	29.07.2020 Bulletin 2020/31

(21)	Application number: 14886988.6

(22)	Date of filing: 28.10.2014

(51)

International Patent Classification (IPC):

G01N 33/574^(2006.01)

C07K 16/30^(2006.01)

(86)	International application number:
	PCT/US2014/062649

(87)	International publication number:
	WO 2015/147915 (01.10.2015 Gazette 2015/39)

(54)	COMPOSITIONS FOR SUPPRESSING CANCER BY INHIBITION OF TMCC3 ZUSAMMENSETZUNGEN ZUR UNTERDRÜCKUNG VON KREBS DURCH TMCC3-HEMMUNG COMPOSITIONS DE SUPPRESSION DU CANCER PAR INHIBITION DE TMCC3

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

24.03.2014 US 201414223800

(43)	Date of publication of application:
	01.02.2017 Bulletin 2017/05

(73)	Proprietors:
	Development Center for Biotechnology New Taipei City 221 (TW) Chang Gung Memorial Hospital Taoyuan County 333 (TW) Academia Sinica Taipei City 11529 (TW)

(72)	Inventors:
	YU, Alice, L. New Taipei City 221 (TW) YU, John New Taipei City 221 (TW) WANG, Ya-Hui New Taipei City 221 (TW) HSU, Chuan-Lung New Taipei City 221 (TW) CHEN, Yi-Chang New Taipei City 221 (TW) LOK, Ying-Yung New Taipei City 221 (TW)

(74)	Representative: Mewburn Ellis LLP
	Aurora Building Counterslip Bristol BS1 6BX Bristol BS1 6BX (GB)

(56)

References cited: :

WO-A2-2012/031008
US-A1- 2013 142 875

US-A1- 2011 119 776
US-A1- 2014 363 372

YA- HUI WANG ET AL: "Abstract 3317: The roles of TMCC3 in breast cancer cells", CANCER RESEARCH, vol. 72, no. 8 Supplement, 15 April 2012 (2012-04-15), pages 3317-3317, XP55356101, & 103RD ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH; CHICAGO, IL, USA; MARCH 31 -APRIL 04, 2012 ISSN: 0008-5472, DOI: 10.1158/1538-7445.AM2012-3317
CHAO ZHANG ET AL: "Transmembrane and Coiled-Coil Domain Family 1 Is a Novel Protein of the Endoplasmic Reticulum", PLOS ONE, vol. 9, no. 1, 14 January 2014 (2014-01-14), page e85206, XP055395163, DOI: 10.1371/journal.pone.0085206
WANG ET AL.: 'Abstract 3317: The roles of TMCC3 in breast cancer cells' AACR 103RD ANNUAL MEETING 2012, CANCER RESEARCH vol. 72, 15 April 2012, page 3317, XP055356101

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).